FDA panel rejects claim that smokeless cigarettes result in less harm and disease; big data might be able to shed light on the health effects of weight gain; healthcare is not a key issue among voters in battleground states.
A panel convened by the FDA has decided that Philip Morris International was not able to conclusively prove that smokeless cigarettes result in less harm and disease. According to The Washington Post, while the advisory panel agreed that the smokeless cigarette reduced exposure to harmful chemicals, it wasn’t clear that it reduces the harm of smoking. The company claimed that the cigarette’s technology, which heats up sticks of tobacco, eliminated 90% to 95% of toxic compounds.
New research may provide a better understanding of the health risks of yo-yo dieting and why gaining weight causes chronic conditions in some people. Scientists determined that more than 300 genes worked differently after most participants in the study gained a little weight, reported The New York Times. The study analyzed the genomes and microbiomes of 23 overweight men and women. The participants were first asked to overeat for a month—gaining an average of 6 pounds—then asked to lose the new weight, and finally told to keep their weight stable and return for testing after 3 months.
While healthcare is the top issue that all registered voters say they want congressional candidates to talk about during 2018 campaigns, it is farther down the list in battleground states. A poll from the Kaiser Family Foundation found that in areas with competitive races, the economy and jobs were the top issue and healthcare ranked fourth overall. Voters in battleground states also placed the situation with North Korea and immigration ahead of healthcare. Battle ground states were identified as 13 states where the upcoming election results are judged as a toss-up by a nonpartisan organization.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More